SIGA Technologies, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- SIGA Technologies, Inc. (Nasdaq: SIGA) is a commercial-stage pharmaceutical company focused on developing and commercializing innovative antiviral therapeutics for infectious diseases, particularly orthopoxviruses such as smallpox, mpox, cowpox, and vaccinia complications; its lead product is TPOXX (tecovirimat), available in oral and intravenous formulations approved by the U.S. FDA for smallpox treatment, by Health Canada for the same indication, in the European Union, UK, Norway, Iceland, and Liechtenstein as Tecovirimat SIGA for orthopoxvirus infections, and in Japan as TEPOXX for smallpox, mpox, cowpox, and vaccination complications in adults and pediatric patients weighing at least 13 kg. Founded in 1995 and headquartered in New York, New York, the company primarily serves government stockpiles and public health agencies worldwide, including long-term partnerships with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for Strategic National Stockpile (SNS) procurement and deliveries exceeding $1 billion over the past decade; it operates in over 30 countries with international sales to entities like Japan's SNS, Morocco's Ministry of Health, and recurring customers in multiple regions. Recent developments include BARDA contract modifications in 2025 adding $27 million for TPOXX pediatric development and manufacturing, a $26 million IV TPOXX procurement order from the U.S. Government in March 2025, TEPOXX regulatory approval in Japan in January 2025 as the first antiviral for orthopoxviruses there, a revised high-single-digit fee agreement with promoter Meridian Medical Technologies effective June 2024, first entry into the African market via a $0.8 million TPOXX supply deal with Morocco in 2024, $139 million in 2024 global revenues driven by TPOXX deliveries including $51.2 million under a July 2024 BARDA option and $11 million in Japan-related international sales, and ongoing preparations for a new U.S. Government contract for oral and IV TPOXX potentially valued similarly to the prior $546 million award with deliveries anticipated in 2026.
Siga Technologies Q1 Earnings Call Highlights
SIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call Transcript
SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update
SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results
JPMorgan Chase & Co. Increases Stake in Siga Technologies Inc. $SIGA
Siga Technologies Sees Unusually High Options Volume (NASDAQ:SIGA)
Siga Technologies (NASDAQ:SIGA) and CASI Pharmaceuticals (NASDAQ:CASI) Financial Comparison
Why Are Siga Technologies Shares Trading Higher?
SIGA Declares Special Cash Dividend of $0.60 Per Share
EOM Pharmaceutical (OTCMKTS:IMUC) & Siga Technologies (NASDAQ:SIGA) Financial Survey
SIGA Technologies, Inc. (SIGA) Q4 2025 Earnings Call Transcript
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2025 and Provides Business Update
SIGA to Host Business Update Call on March 10, 2026, Following Release of 2025 Financial Results
Stock Traders Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)
Traders Purchase Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)
Takeda Pharmaceutical (NYSE:TAK) vs. Siga Technologies (NASDAQ:SIGA) Head-To-Head Review
Siga Technologies Sees Unusually Large Options Volume (NASDAQ:SIGA)
Siga Technologies Inc. $SIGA Shares Sold by Aviva PLC
SIGA Technologies, Inc. (SIGA) Q3 2025 Earnings Call Transcript
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025